Abbott's Medical Devices Momentum Persists, but Integration and Litigation Clouds Remain

What happened

Abbott's Medical Devices segment, its largest, is building on strong growth with new product advances in diabetes, heart rhythm, and electrophysiology ahead of Q2 2026 results, as highlighted in a recent Zacks article. The DeepValue Master Report confirms Devices momentum, with 1Q26 Medical Devices sales up 8.1% ex-FX and CGM sales reaching $2.0B, but notes that the Exact Sciences acquisition and ongoing NEC infant-formula litigation create significant near-term uncertainty. The report assigns a WAIT rating with an attractive entry at $82, citing the need for evidence that Diagnostics growth can accelerate and that dilution from the Exact deal stays within guided ranges. Key risks include FDA compliance issues with Libre 3 sensors, which could disrupt the Devices growth engine, and the potential for additional large NEC verdicts before the bellwether trials in August 2026. While the article highlights the segment's growth prospects, the DeepValue analysis underscores that the stock's next leg depends on containing these non-linear risks, making a cautious stance advisable.

Implication

The near-term outlook for Abbott is dominated by the need to prove that the Exact Sciences acquisition can accelerate Diagnostics growth, as 1Q26 saw only a $96M contribution post-close and overall Diagnostics growth was weak. Medical Devices, particularly CGM, remains a bright spot but faces regulatory risk from the FDA warning letter and Class I recall on Libre 3, which could threaten supply continuity and market share. NEC litigation continues to be a headline risk, with a $70M jury award in April 2026 and a bellwether trial set for August 2026; further adverse verdicts could reset settlement expectations and pressure the stock. Balance sheet flexibility (net debt/EBITDA 0.6, A+ credit) provides a cushion, but integration costs and elevated SG&A have already compressed margins, and any deviation from the FY26 EPS guidance of $5.38-$5.58 would trigger a re-rating. The current price around $86.6 is near the midpoint of the bear and base case scenarios, implying limited upside without clear catalysts; the recommended re-assessment window is 3-6 months, waiting for Q2 and Q3 evidence.

Thesis delta

The DeepValue thesis remains WAIT, as the stock's risk/reward is balanced but hinges on de-risking integration and litigation. The positive Medical Devices news is consistent with the existing thesis but does not change the need for evidence of Diagnostics acceleration and containment of the NEC legal overhang. No shift in rating is warranted; the key checkpoints are Q2 2026 results and the August bellwether trial outcomes.